Revive Therapeutics and South Carolina Research Foundation Enter into Exclusive License Agreement for Cannabinoids-Based Therapeutics in the Treatment of Liver Diseases

TORONTO, ONTARIO--(Sept. 19, 2017) - Revive Therapeutics Ltd. ("Revive" or the "Company") (TSX VENTURE:RVV)(OTCQB:RVVTF), a company focused on the research, development and commercialization of novel treatments for serious and unmet medical needs, today announced that it has entered into a license agreement with South Carolina Research Foundation ("SCRF"), under which Revive will acquire an exclusive license from SCRF to develop and commercialize a portfolio of patents based on cannabinoid-based therapeutics, such as Cannabidiol, in the treatment of liver diseases.
Read more: Revive Therapeutics Ltd ( RVV )

Prometic Reports Positive Clinical Data from Ongoing PBI-4050 Study in Alström Syndrome Patients

Sustained safety observed over 48 weeks of treatment
Beneficial clinical effects in liver sustained over 48 weeks of treatment
Positive results support requests for meetings with both FDA and EMA to define the clinical-regulatory pathway for approval of PBI-4050 for the treatment of Alström syndrome
 
LAVAL, QC, Sept. 19, 2017 - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) (Prometic) today announced that longer-term data from its on-going phase 2 open label clinical trial in subjects suffering from Alström Syndrome in the United Kingdom confirm that the beneficial clinical effects previously observed are sustained during prolonged treatment.
Read more: Prometic Life Sciences ( PLI )

iBio and TheoremDx Collaborate to Develop Proteins for Rapid Diagnostics Testing Products

NEW YORK, Sept. 18, 2017  -- iBio, Inc. (NYSE AMERICAN:IBIO) – iBio, with its subsidiary, iBio CDMO LLC in Bryan/College Station, Texas ("iBio CDMO"), has partnered with TheoremDx, Inc., in Edina, Minnesota, to develop proteins for rapid diagnostic testing products.
 
The collaboration will leverage the TheoremDx point-of-care diagnostic system and the protein development and manufacturing capabilities of iBio. The goal of the collaboration is to serve the citizens of the US and the world through the rapid development and manufacturing of proprietary plant proteins for point-of-care diagnostic testing products. 
Read more: iBio Inc ( IBIO )

NIH Awards $1.8 Million Research Grant  to Pain Therapeutics in Support of a Blood-based Diagnostic for Alzheimer ’s Disease

AUSTIN, Texas, Sept. 18, 2017  -- Pain Therapeutics, Inc. (Nasdaq:PTIE), a biopharmaceutical company, announced today it has been awarded an approximately $1.8 million research grant from the National Institutes of Health (NIH).  This grant will support innovative technology developed by the Company to diagnose Alzheimer’s disease with a simple blood test.
 
“Finding a way to diagnose disease at an early-stage is vitally important,” said Remi Barbier, President & CEO of Pain Therapeutics.  “A blood test may help detect Alzheimer’s disease before symptoms occur, or rule out other possible causes of memory problems, or might be used as a biomarker to measure the efficacy of drug candidates during clinical trials.”
Read more: Pain Therapeutics Inc ( PTIE )

ITUS Corporation Announces Issuance of Patent on Cancer Detection Technology

SAN JOSE, CA--(September 18, 2017) - ITUS Corporation (NASDAQ: ITUS), today announced that the United States Patent and Trademark Office ("USPTO") has issued U.S. Patent 9,739,783, to inventors Dr. Amit Kumar, Chief Executive Officer, and John Roop, VP of Engineering, of ITUS Corporation. ITUS's early cancer detection technology is being developed by its wholly owned subsidiary, Anixa Diagnostics Corporation.
 
Dr. Kumar stated, "This is the first patent to issue of several patents that we expect to issue garnering protection of our cancer detection technology. The claims of this patent were allowed in May of 2017, and now we have received the official issuance notification and patent number. We currently have one other key patent application pending at the USPTO and expect to file for additional patent protection as our research and development continues."
Read more: ITUS Corporation ( ITUS )

Videos / Webinars

View all videos

Pepperstone | Metatrader 4 Forex Broker